Drugs / Anrikefon
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07826806 | Sep 2026 → Dec 2027 expected | — | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07514637 | Nov 2025 → Mar 2026 overdue | — | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT07825142 | Oct 2026 → Jul 2029 expected | nephrolithiasis | Beijing Tsinghua Chang Gung Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07380113 | Jul 2026 → Dec 2027 expected | chronic kidney disease, uremia | Zhujiang Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07525986 | Apr 2026 → Mar 2027 expected | — | Peking University First Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07269106 | Jan 2026 → Dec 2027 expected | — | Zhongshan Ophthalmic Center, Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 4 | NCT07246785 | Dec 2025 → Feb 2026 | — | Peking University First Hospital | Terminated | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07810413 | Sep → Dec 2026 expected | — | The First People's Hospital of Lianyungang | Not yet recruiting | No outcome recorded |
| — | NCT07566663 | Jun 2026 → May 2028 expected | — | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| — | NCT07353983 | Jan 2026 overdue | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anrikefon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07826806 ↗ |
| Known as | HSK21542 | “BACKGROUND: Anrikefon (HSK21542), a potent and selective peripheral kappa opioid receptor (KOR) agonist developed by Haisco, effectively blocks pain and itch signals.” PMID 39825476 ↗ Jan 20251“evaluating the efficacy and safety of Anrikefon (HSK21542) Injection” NCT07810413 ↗ |
| Action | Activate | “Anrikefon is a novel selective peripheral κ-opioid receptor agonist.” NCT07246785 ↗ |
| Route | Intravenous | “a single intravenous dose of Anrikefon effectively alleviates pain after abdominal surgery” NCT07246785 ↗ |